肉瘤新药他泽司他(Tazemetostat)治疗效果怎么样？有副作用吗？

Tazemetostat, an inhibitor of histone lysine methyltransferase EZH2, was launched in the United States in 2020 and is mainly used to treat metastatic/locally advanced epithelioid sarcoma that is not suitable for complete resection. The drug, developed and produced by Epizyme, is the first treatment specifically for epithelioid sarcoma. Today let’s take a closer look at the therapeutic effects of (Tazemetostat)? Are there any side effects?

A trial of 62 patients with epithelioid sarcoma who took tazerestat orally twice daily showed a complete response in 1.6% of patients, an overall objective response rate (ORR) of 15%, and a partial response rate of 13%. Moreover, 67% of patients whose tumors did not shrink but whose condition did not worsen continued to respond for more than half a year or even longer. In another trial, patients with loss of INI1 protein expression were treated with tazerestat. Among a total of 62 patients, 13% of patients achieved partial response, 1.6% achieved complete response, and the overall response rate (ORR) was 15%. Of the 9 patients who responded, 6 (67%) had responses that lasted 6 months or longer. The trial shows that the new drug Tazemetostat has a significant therapeutic effect on sarcoma.

So, what are the side effects of the new sarcoma drug Tazemetostat? Nausea, decreased appetite, upper respiratory tract infection, fatigue, vomiting, constipation, musculoskeletal pain, aches, abdominal pain, etc., but overall safety is tolerated. Patients should pay attention to their own reactions during medication. If unbearable side effects occur, contact the doctor for symptomatic treatment in a timely manner without delay, so as not to delay the condition.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: